54-86-4

Usage

Uses

Used in Pharmaceutical Industry:
SODIUM NICOTINATE is used as an intermediate for the development of various pharmaceutical products. It plays a crucial role in the synthesis of medications that target a wide range of health conditions, including cardiovascular diseases and skin disorders.
Used in Cosmetic Industry:
SODIUM NICOTINATE is used as an active ingredient in the cosmetic industry for its skin-beneficial properties. It is commonly utilized in the formulation of skincare products, such as creams, lotions, and serums, due to its ability to improve skin health and appearance.

InChI:InChI=1/C6H5NO2.Na/c8-6(9)5-2-1-3-7-4-5;/h1-4H,(H,8,9);/q;+1/p-1

Upstream product

• 93-60-7 methyl 3-pyridinecarboxylate 
• 59-67-6 nicotinic acid 
• 5657-61-4 nicotinyl hydroxamic acid 

Downstream Products

• 10400-19-8 3-pyridinecarbonyl chloride 
• 66148-15-0 d4-nicotinic acid 
• 120155-05-7 7-benzyloxy-6-methoxy-1-methylene-2-nicotinyl-1,2,3,4-tetrahydroisoquinoline 
• 120155-02-4 11-benzyloxy-10-methoxy-7,8-dihydro-5H-benzopyrido<3,2-g>quinolizin-5-one 
• 104669-20-7 11-benzyloxy-10-methoxy-7,8-dihydro-5H-benzopyrido<3,4-g>quinolizin-5-one 
• 115757-50-1 11-benzyloxy-10-methoxy-7,8-dihydro-5H-benzopyrido<3,4-g>quinolizin-5-thione 
• 94-44-0 benzyl nicotinate 
• 16230-63-0 copper(II) nicotinate 
• 1260234-99-8 C₁₉H₁₅N₅O₃S 
• 7681-15-4 n-propyl nicotinate 
• 28558-40-9 2-oxo-2-phenylethyl riicotinate 
• 86535-76-4 3-phenyl-1-(pyridin-3-yl)prop-2-yn-1-one 
• 1450824-31-3 4-(2-(3-pyridylformyloxy)ethoxy)-3-phenylfuran-2(5H)-one 
• 1537179-03-5 (S)-tert-butyl-2-(nicotinamido)-3-phenylpropanoate 

Relevant academic research and scientific papers

Hydrogen bonds determine the signal arrangement in 13C NMR spectra of nicotinate

Present work reports on studies of sodium nicotinate solutions in water and aqueous ethanol by means of 1H, 13C, 15N NMR spectroscopy. The H(2) nucleus was observed to be the least shielded among pyridine ring protons whil

Mechanistic insights into the: In vitro metal-promoted oxidation of (di)azine hydroxamic acids: Evidence of HNO release and N, O -di(di)azinoyl hydroxylamine intermediate

The oxidant-dependent ability of hydroxamic acids to release nitroxyl (HNO), a small inorganic molecule endowed with various biological properties, is addressed from a mechanistic standpoint. Indeed, the exact mechanism of the hydroxamic acid oxidation in physiological conditions and the direct or indirect characterization of the intermediates remain elusive. In this work, intermolecular oxidation of isonicotino-, nicotino- and pyrazino-hydroxamic acids with K3[FeIII(CN)6] at physiological pH (7.4), was monitored by 1H NMR, MS, EPR and UV-vis techniques. While nitrosocarbonyl (di)azine intermediates, (di)Az-C(O)-NO, could be a priori envisaged, it was in fact the corresponding N,O-di(di)azinoylhydroxylamines (AzC(O)NHOC(O)Az) and HNO that were identified, the first by 1H NMR and the second on the basis of EPR and UV-vis experiments using the [2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide] (cPTIO) spin trap. The decomposition of the unstable N,O-di(di)azinoylhydroxylamine intermediates in aqueous buffer media was shown to generate the corresponding carboxylic acids as final organic products, envisaged as possible in vivo metabolites. The same oxidation experiments performed in the presence of methylamine led to the corresponding N-methyl amides suggesting that, unlike hydroxamic acids, N,O-di(di)azinoylhydroxylamines act as acylating agents in physiological pH conditions.

HDL-boosting combination therapy complexes

A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent.